Current Medicinal Chemistry - Central Nervous System Agents
Title: subject Index To Volume 2
Volume: 3 Issue: 1
Author(s): Bentham Science Publishers
Affiliation:
Export Options
About this article
Cite this article as:
Bentham Science Publishers , subject Index To Volume 2, Current Medicinal Chemistry - Central Nervous System Agents 2003; 3 (1) . https://dx.doi.org/10.2174/1568015033357706
DOI https://dx.doi.org/10.2174/1568015033357706 |
Print ISSN 1568-0150 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6158 |
Article Metrics
Related Articles
-
Application of Mitochondria-Targeted Pharmaceuticals for the Treatment of Heart Disease
Current Pharmaceutical Design Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier
Current Pharmaceutical Design Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry COXIBs, CINODs and H2S-Releasing NSAIDs: Current Perspectives in the Development of Safer Non Steroidal Anti-Inflammatory Drugs
Current Medicinal Chemistry Disruption of Circadian Rhythms and Sleep on Critical Illness and the Impact on Cardiovascular Events
Current Pharmaceutical Design Simultaneous Separation, Quantitation, and Determination of the Dissociation Constant of Five Components of Ixeris sonchifolia by Microemulsion Electrokinetic Chromatography
Current Pharmaceutical Analysis HspB5/αB-Crystallin: Properties and Current Progress in Neuropathy
Current Neurovascular Research COX-2 in Brain and Spinal Cord - Implications for Therapeutic Use.
Current Medicinal Chemistry Angiotensin Converting Enzyme Inhibitor in Coronary Artery Bypass Surgery
Drug Design Reviews - Online (Discontinued) α-Fibrinogenases
Current Drug Targets - Cardiovascular & Hematological Disorders Cardiac Stem Cell Regeneration in Metabolic Syndrome
Current Pharmaceutical Design Toll-Like Receptor (TLR) Response Tolerance: A Key Physiological “ Damage Limitation ” Effect and an Important Potential Opportunity for Therapy
Current Medicinal Chemistry Progress in Drug Treatment of Cerebral Edema
Mini-Reviews in Medicinal Chemistry Biological Therapies: Effects of Proinflammatory Pathways and their Inhibition on the Myocardium of Rheumatoid Athritis Patients
Current Medicinal Chemistry Advances in Drug Safety
Current Pharmaceutical Design Editorial (Hot Topic: No Reflow: What’s in a Name?)
Current Pharmaceutical Design Novel Trends in the Treatment of Cardiovascular Disorders: Site- and Event- Selective Adenosinergic Drugs
Current Medicinal Chemistry The Discovery of the Factor Xa Inhibitor Otamixaban: From Lead Identification to Clinical Development
Current Medicinal Chemistry From Preclinical to Clinical Trials: An Update on Potential Therapies for Huntington’s Disease
Current Psychopharmacology The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry